Among drugs granted accelerated approval by the U.S. Food and Drug Administration (FDA) in 2009-2013, efficacy was often confirmed in subsequent trials a minimum of 3 years after approval, and the use of nonrandomized studies and surrogate measures, instead of clinical outcomes, was common, according to a study published August 15th 2017 by JAMA. A… Continue reading Examining the Quality of Evidence for Drugs Granted Accelerated FDA Approval